Rapid Micro Biosystems Sees Revenue Dip Amidst Product Sales Slump

TL;DR

RPID's revenue is shrinking, especially in products, making it a risky bet for traders looking for growth.

AI Summary

RAPID MICRO BIOSYSTEMS, INC. reported total revenue of $6.0 million for the three months ended June 30, 2025, a decrease from $6.4 million in the prior-year period. Product revenue declined to $3.5 million from $4.0 million, while service revenue remained relatively stable at $2.5 million compared to $2.4 million. For the six months ended June 30, 2025, total revenue was $12.0 million, down from $12.5 million in the same period of 2024. The company's net loss for the three months ended June 30, 2025, was not explicitly detailed in the provided snippet, but the overall revenue decline suggests continued financial challenges. Key business changes include a slight shift in revenue mix, with services holding steady despite product revenue contraction. Risks include ongoing revenue decline, particularly in product sales, which could impact future profitability and cash flow. The strategic outlook appears focused on maintaining service revenue while addressing product sales performance, though specific strategies are not detailed in this excerpt.

Why It Matters

RAPID MICRO BIOSYSTEMS' continued revenue decline, particularly in product sales, signals potential challenges in market penetration and competitive positioning within the laboratory analytical instruments sector. For investors, this trend could indicate a struggle to achieve profitability and may impact stock valuation, especially given the competitive landscape with larger, more established players. Employees might face uncertainty if revenue contraction leads to cost-cutting measures. Customers could see potential impacts on product development or support if the company's financial health deteriorates. The broader market for lab instruments will watch to see if this is an isolated issue or indicative of wider industry pressures.

Risk Assessment

Risk Level: high — The company reported a decline in total revenue to $6.0 million for Q2 2025 from $6.4 million in Q2 2024, representing a 6.25% decrease. Product revenue specifically fell from $4.0 million to $3.5 million, indicating a significant challenge in its core offering. This consistent revenue contraction, as seen in the six-month period ($12.0 million in 2025 vs. $12.5 million in 2024), points to ongoing operational difficulties and increased financial risk.

Analyst Insight

Investors should exercise caution and consider holding off on new investments in RPID until there's clear evidence of revenue stabilization or growth. Current investors should re-evaluate their position, as the declining product revenue suggests fundamental business challenges that could impact long-term value.

Financial Highlights

revenue

$6.0M

revenue Growth

-6.25%

Revenue Breakdown

Key Numbers

• $6.0M — Total Revenue (Q2 2025) (Decreased from $6.4M in Q2 2024, indicating a 6.25% decline.)
• $3.5M — Product Revenue (Q2 2025) (Fell from $4.0M in Q2 2024, highlighting a core business challenge.)
• $2.5M — Service Revenue (Q2 2025) (Remained stable compared to $2.4M in Q2 2024, providing some stability.)
• $12.0M — Total Revenue (YTD June 2025) (Down from $12.5M in the prior year, showing a consistent downward trend.)
• 6.25% — Q2 Revenue Decline (Percentage decrease in total revenue from Q2 2024 to Q2 2025.)

Key Players & Entities

• RAPID MICRO BIOSYSTEMS, INC. (company) — filer of the 10-Q
• $6.0 million (dollar_amount) — total revenue for Q2 2025
• $6.4 million (dollar_amount) — total revenue for Q2 2024
• $3.5 million (dollar_amount) — product revenue for Q2 2025
• $4.0 million (dollar_amount) — product revenue for Q2 2024
• $2.5 million (dollar_amount) — service revenue for Q2 2025
• $2.4 million (dollar_amount) — service revenue for Q2 2024
• $12.0 million (dollar_amount) — total revenue for six months ended June 30, 2025
• $12.5 million (dollar_amount) — total revenue for six months ended June 30, 2024
• Bloomberg (company) — publisher of the analysis

FAQ

Risk Factors

• Declining Revenue Trend [high — financial]: Total revenue for Q2 2025 was $6.0 million, a decrease from $6.4 million in Q2 2024. This 6.25% decline, particularly in product revenue which fell 12.5% to $3.5 million, raises concerns about the company's ability to generate sales and sustain operations.
• Profitability Concerns [high — financial]: The continued revenue decline, especially in product sales, suggests potential pressure on gross margins and overall profitability. Without a clear turnaround in sales, the company may struggle to achieve profitability and manage its cash flow effectively.
• Competitive Landscape [medium — market]: The company operates in the laboratory analytical instruments market, which can be competitive. Failure to innovate or adapt to market demands could lead to further erosion of market share and revenue.
• Dependence on Product Sales [medium — operational]: While service revenue is stable, the significant drop in product revenue highlights a potential over-reliance on a segment that is currently underperforming. Diversifying revenue streams or revitalizing product offerings is crucial.

Industry Context

Rapid Micro Biosystems operates within the laboratory analytical instruments sector, a field characterized by technological innovation and stringent regulatory requirements. The industry demands continuous development of accurate and efficient diagnostic tools for various applications, including healthcare and industrial quality control. Competition is often driven by performance, cost-effectiveness, and the ability to meet evolving scientific and regulatory standards.

Regulatory Implications

Companies in the laboratory analytical instruments space are subject to regulatory oversight, particularly if their products are used in healthcare diagnostics. Compliance with standards set by bodies like the FDA (if applicable) is critical for market access and product approval. Any changes in regulatory requirements or failure to maintain compliance can significantly impact product development, sales, and overall business operations.

What Investors Should Do

1. Monitor product sales performance closely.
2. Assess the sustainability of service revenue.
3. Evaluate the company's cash burn and runway.

Glossary

10-Q

A quarterly report filed by public companies with the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive overview of a company's financial performance. (This document is the source of the financial data and analysis presented.)

Product Revenue

Revenue generated from the sale of the company's physical products, such as instruments or consumables. (A key segment of Rapid Micro Biosystems' revenue, which has shown a significant decline.)

Service Revenue

Revenue generated from services provided by the company, such as maintenance, support, or software subscriptions. (This segment has remained stable, offering some resilience to the company's overall financial performance.)

Year-Over-Year Comparison

Compared to the prior year's filing period, Rapid Micro Biosystems has experienced a notable decline in total revenue, falling from $12.5 million year-to-date in 2024 to $12.0 million in 2025. This trend is primarily driven by a decrease in product revenue, which dropped from $4.0 million to $3.5 million in the second quarter alone. While service revenue has shown slight growth, the overall revenue contraction suggests a worsening financial performance and potential challenges in market demand or competitive positioning.

Key Financial Figures

• $0.01 — which registered Class A common stock, $0.01 par value per share RPID The Nasdaq Ca
• $0 — trant's Class A common stock, par value $0.01, outstanding. As of August 8, 2025,

Filing Documents

• rmb-20250630.htm (10-Q) — 1629KB
• rpid_rpid-20250630xexx101x.htm (EX-10.1) — 3KB
• ex_102xtrinityxrpidxloanan.htm (EX-10.2) — 602KB
• rpid-exx103_trinityxrpidxw.htm (EX-10.3) — 120KB
• rpid-20250630xexx311.htm (EX-31.1) — 11KB
• rpid-20250630xexx312.htm (EX-31.2) — 11KB
• rpid-20250630xex321.htm (EX-32.1) — 5KB
• rpid-20250630xex322.htm (EX-32.2) — 5KB
• image_0.jpg (GRAPHIC) — 29KB
• image_01.jpg (GRAPHIC) — 0KB
• rmb-20250630_g1.jpg (GRAPHIC) — 11KB
• 0001380106-25-000174.txt ( ) — 8941KB
• rmb-20250630.xsd (EX-101.SCH) — 49KB
• rmb-20250630_cal.xml (EX-101.CAL) — 73KB
• rmb-20250630_def.xml (EX-101.DEF) — 264KB
• rmb-20250630_lab.xml (EX-101.LAB) — 706KB
• rmb-20250630_pre.xml (EX-101.PRE) — 480KB
• rmb-20250630_htm.xml (XML) — 1141KB

Financial Statements

Financial Statements 6 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 (Unaudited) 6 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 (Unaudited) 7 Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 (Unaudited) 8 Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and 2024 (Unaudited) 9 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 (Unaudited) 10 Notes to Condensed Consolidated Financial Statements (Unaudited) 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 29 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 44 Item 4.

Controls and Procedures

Controls and Procedures 44 Part II Other Information Item 1.

Legal Proceedings

Legal Proceedings 46 Item 1A.

Risk Factors

Risk Factors 46 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 79 Item 3. Defaults Upon Senior Securities 79 Item 4. Mine Safety Disclosures 79 Item 5. Other Information 79 Item 6. Exhibits 80 Exhibit Index 80

Signatures

Signatures 81 2 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "forecasts," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements regarding: our business strategy for our Gro wth Direct platform and systems; our future results of operations and financi al position, including our expectations regarding revenue, gross margin, operating expenses and our ability to achieve positive cash flow; our goal to achieve positive cash flow by the end of 2027, our efforts to reduce our use of cash for operating and investing activities and the assumptions underlying such goal; the expected impact of our recently-announced debt facility with Trinity Capital Inc., including with respect to our financial position, cash forecast and use of proceeds; our expectations and assumptions related to our future funding requirements and available capital resources, which may be impacted by market uptake of our Growth Direct platform and systems, our management of inventory and supply chain, our capital expenditures, our research and development activities and our sales, marketing, manufacturing and distribution activities; our ability to maintai

—FINANCIAL INFORMATION

PART I —FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements RAPID MICRO BIOSYSTEMS, INC. Condensed consolidated balance sheets (Unaudited) (In thousands, except share and per share amounts) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 18,333 $ 16,911 Short-term investments 12,922 33,821 Accounts receivable 6,048 7,519 Inventory 20,560 20,200 Prepaid expenses and other current assets 2,283 2,466 Total current assets 60,146 80,917 Property and equipment, net 10,205 11,193 Right-of-use assets, net 4,640 5,163 Other long-term assets 311 531 Restricted cash 284 365 Total assets $ 75,586 $ 98,169 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 3,334 $ 2,535 Accrued expenses and other current liabilities 5,678 7,217 Deferred revenue 6,136 6,599 Lease liabilities, short-term 1,255 1,214 Total current liabilities 16,403 17,565 Lease liabilities, long-term 4,324 4,954 Other long-term liabilities 314 298 Total liabilities 21,041 22,817 Commitments and contingencies (Note 14) Stockholders' equity: Class A common stock, $ 0.01 par value; 210,000,000 shares authorized at June 30, 2025 and December 31, 2024; 39,560,439 shares and 37,729,242 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 395 377 Class B common stock, $ 0.01 par value; 10,000,000 shares authorized at June 30, 2025 and December 31, 2024; 4,499,529 shares and 5,309,529 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 45 53 Preferred stock, $ 0.01 par value: 10,000,000 shares authorized at June 30, 2025 and December 31, 2024; zero shares issued and outstanding at June 30, 2025 and December 31, 2024 — — Additional paid-in capital 552,502 550,157 Accumulated deficit ( 498,395 ) ( 475,274 ) Accumulated other comprehensive income ( 2 ) 39 Total stockholders' equity 54,545 75,352 Total liabilities and stockholders' equity $ 75,586 $ 98,169 The accompanying notes are an integ

View Full Filing

View this 10-Q filing on SEC EDGAR